Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 253 participants.

Also called NCT06212648

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 253 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06212648
Other papers using this trial's data
  • Multicenter, Randomized, Double-Blind, Parallel, Phase 2 Clinical Trial to Compare and Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension Clinical therapeutics, 2025-12 DOI, PubMed 41162308 PubMed links an erratum for this paper. Erratum: PMID 41402189

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06212648. Randomized; double masking; primary purpose treatment. Start 2022-03-25 (actual); primary completion 2022-11-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension
Acronym
SP-CAP-002
Condition
Hypertension
Condition
Essential Hypertension
Intervention (Drug)
SPC1001 High
Intervention (Drug)
SPC1001 Mid1
Intervention (Drug)
SPC1001 Mid2
Intervention (Drug)
SPC1001 Low
Intervention (Drug)
SPC3001
Intervention (Drug)
SPC4001
Intervention (Drug)
SPC4002
Intervention (Drug)
Placebo
Lead sponsor
Shin Poong Pharmaceutical Co. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06212648
Content hash
e47f57dd0e9d55578dd3ed04cc200c5f26f96e90fb18b1b17b1260523ed5178b